Status:
COMPLETED
A Study to Assess Adverse Events and Change in Disease State in Adult Participants Being Treated With Humira in Participants Diagnosed With Pyoderma Gangrenosum (PG)
Lead Sponsor:
AbbVie
Conditions:
Pyoderma Gangrenosum
Eligibility:
All Genders
15+ years
Brief Summary
Pyoderma Gangrenosum (PG) is a rapidly progressive disease and presents as painful, single or multiple lesions, with several clinical variants, in different locations, with a nonspecific histology, wh...
Eligibility Criteria
Inclusion
- Diagnosed with Pyoderma Gangrenosum (PG).
- Have been prescribed Humira for PG treatment within 14 days.
Exclusion
- \- Have Pyoderma Gangrenosum (PG) in previous treatment with Humira.
Key Trial Info
Start Date :
February 12 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 11 2024
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04750213
Start Date
February 12 2021
End Date
November 11 2024
Last Update
July 17 2025
Active Locations (46)
Enter a location and click search to find clinical trials sorted by distance.
1
NHO Nagoya Medical Center /ID# 246013
Nagoya, Aichi-ken, Japan, 460-0001
2
Nagoya City University Hospital /ID# 233778
Nagoya, Aichi-ken, Japan, 467-8602
3
Akita University Hospital /ID# 242706
Akita, Akita, Japan, 010-8543
4
Kyushu University Hospital /ID# 247492
Fukuoka, Fukuoka, Japan, 812-8582